PubRank

Clinical and experimental pharmacology & physiology. Supplement (Clin Exp Pharmacol Physiol Suppl)

Journal PubWeight™ 107.61‹?›

Top papers

Rank Title Year PubWeight™‹?›
1 Interaction of circulating hormones with the brain: the roles of the subfornical organ and the organum vasculosum of the lamina terminalis. 1998 1.20
2 Clinical experience with the angiotensin converting enzyme inhibitor captopril. 1982 1.08
3 Molecular and structural biology of thyroid hormone receptors. 1998 1.06
4 Dopamine sulphate: an enigma resolved. 1999 1.02
5 Cortisol and hypertension. 1998 1.01
6 Correlation between angiotensin converting enzyme inhibition and the acute hypotensive response to MK 421 in essential hypertension. 1982 0.99
7 Arterial baroreceptor resetting: contributions of chronic and acute processes. 1989 0.99
8 Physiological actions of angiotensin II mediated by AT1 and AT2 receptors in the brain. 1996 0.96
9 Baroreceptor resetting and other determinants of baroreflex properties in hypertension. 1989 0.96
10 Prevalence of overweight and hypertension in Tanzania: special emphasis on resting energy expenditure and leptin. 2002 0.95
11 Treatment of hypertension with angiotensin converting enzyme inhibitors. 1982 0.92
12 Arterial baroreceptor resetting in hypertension (the J. W. McCubbin memorial lecture). 1989 0.92
13 Gene-environment interaction in hypertension, stroke and atherosclerosis in experimental models and supportive findings from a world-wide cross-sectional epidemiological survey: a WHO-cardiac study. 1992 0.90
14 Effect of perindopril on the development of atherosclerosis in the cholesterol-fed rabbit. 1992 0.88
15 Vascular effects of selected antihypertensive drugs derived from traditional medicinal herbs. 1995 0.88
16 Peripheral and central mechanisms of baroreflex resetting. 1989 0.87
17 Complications of tumour overkill when associated with high dose methotrexate therapy. 1979 0.86
18 Non-neuronal dopamine in the gastrointestinal system. 1999 0.86
19 Angiotensin II is concentrated or locally produced in rat adrenal gland. 1982 0.86
20 Molecular mechanisms of angiotensin II (AT1A) receptor endocytosis. 1996 0.85
21 Decreased sensitivity to beta-adrenergic stimulation of the ventricular cells isolated from the spontaneously hypertensive rat heart. 1995 0.83
22 Verapamil: a selective antagonist of constrictor substances in dog coronary artery: implications for variant angina. 1982 0.83
23 Origins of zonation: the adrenocortical model of tissue development and differentiation. 1998 0.83
24 Sesame lignans modulate cholesterol metabolism in the stroke-prone spontaneously hypertensive rat. 1995 0.83
25 Differences in the characterization of the Ca2+ current in ventricular myocytes between spontaneously hypertensive rats and normotensive rats. 1995 0.83
26 Acute and chronic effects of angiotensin-converting enzyme inhibitors on tissue angiotensin-converting enzyme. 1992 0.82
27 Enhanced contraction to noradrenaline, serotonin and nerve stimulation but normal endothelium-derived relaxing factor response in skin small arteries in human primary hypertension. 1992 0.82
28 Protective effect of thromboxane synthetase inhibitor on hypertensive renal damage in Dahl salt-sensitive rats. 1995 0.81
29 Effects of (-)-epigallocatechin-3-O-gallate (green tea tannin) on the life span of stroke-prone spontaneously hypertensive rats. 1995 0.81
30 Characterization of retinal vascular abnormalities in lean and obese spontaneously hypertensive rats. 1995 0.81
31 Receptor density in the rat heart following ischaemia and prolonged reperfusion. 1995 0.81
32 Nitric oxide in atherosclerosis: vascular protector or villain? 1998 0.81
33 Mapping of angiotensin II receptor subtypes in peripheral tissues of spontaneously hypertensive rats by in vitro autoradiography. 1995 0.81
34 Comparison of the pharmacokinetics and pharmacodynamics of perindopril, cilazapril and enalapril. 1992 0.81
35 Mechanisms for preserved cerebrovascular autoregulation during hypertension in rats after sinoaortic denervation. 1995 0.81
36 Methotrexate nephrotoxicity. 1979 0.81
37 The development of captopril and its role in the treatment of hypertension. 1982 0.81
38 Acceleration of renal disease in obese SHR by exacerbation of hypertension. 1995 0.80
39 Increased vasodilator response during stimulation of cardiopulmonary baroreceptors in borderline hypertensives. 1989 0.80
40 The effects of vasoactive peptides on the carotid cardiac baroreflex. 1982 0.80
41 Regulation of aldosterone biosynthesis: the end of the road? 1998 0.80
42 Antihypertensive effect of thermolysin digest of dried bonito in spontaneously hypertensive rat. 1995 0.80
43 Enalapril improves glucose tolerance in two rat models: a new hypertensive diabetic strain and a fructose-induced hyperinsulinaemic rat. 1995 0.80
44 Converting enzyme inhibition: implications for renal perfusion and function. 1982 0.80
45 Verapamil and beta-adrenoceptor blockade in the treatment of stable angina pectoris. 1982 0.80
46 Toxic rash associated with high dose methotrexate therapy. 1979 0.80
47 Role of AT1 receptors in the central control of sympathetic vasomotor function. 1996 0.80
48 Alternative splicing of natriuretic peptide A and B receptor transcripts in the rat brain. 1995 0.80
49 Alteration in the release of endothelium-derived relaxing factors by alpha-adrenoceptor stimulation in the aorta of stroke-prone spontaneously hypertensive rats. 1995 0.79
50 The renin-angiotensin system and hypertension. 1982 0.79
Next 50